However, one of the major challenges in the treatment of HER2-positive metastatic breast cancer is brain metastases, in which a previous study demonstrated that up to 50% of the metastatic HER2-positive breast cancer patients eventually died of central nervous system (CNS) progression (10). This evidence concerns the gene ERBB2 and breast carcinoma.